Fundraising FoxHatteras Venture Partners — 2021 Investments
7 investments dated 2021 · listed companies and verified rows first · show all
Trefoil Therapeutics is a clinical-stage biotechnology company developing therapeutic agents for corneal diseases.
BiotechHealthtechMedical DevicesSan Diego, US
David Eveleth(Executive Officer, Director)inSchalon Newton(Executive Officer)in
BoardChristy Shaffer(Director)inRalph Bradshaw(Director)
Co-investorsBios PartnersExSight VenturesSolasta VenturesAccess BiotechnologyCorrelation VenturesFemHealth Ventures+1 more
StrideBio develops gene therapies based on its STRIVE AAV capsid platform, targeting people with life-threatening diseases.
BiotechHealthtechDurham, US
Aravind Asokan(Director)inMavis Abjandje-McKenna(Director)Richard Smith(Executive Officer)inPatrick Ritschel(Executive Officer, Director, Promoter)
Board seatClay ThorpMike Dial· per SEC Form D
Co-investorsPontifax Venture CapitalAbingworthDe Novo VenturesNorthpond Ventures
An R&D-driven biopharmaceutical company that uses AI to develop breakthrough medicines and vaccines focused on immune system disorders across five therapeutic areas.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Ivana Magovcevic-Liebisch(Executive Officer, Director)Christopher Verni(Executive Officer)inMary Thistle(Director)Evan Thackaberry(Executive Officer)Suzanne Bruhn(Director)Gerhard Koenig(Director)
Board seatClay Thorp· per SEC Form D
Co-investorsAtlas VentureLightstone VenturesPivotal Life SciencesVida VenturesLongwood Fund
Sensorium Therapeutics is a clinical-stage biotech company developing novel CNS therapies for anxiety, epilepsy, and cognitive dysfunction using its SensAI platform, which integrates AI, chemistry, and curated natural product data to identify therapeutic patterns from over 50 million biological relationships.
AI & Machine LearningBiotechDigital HealthMedford, US
Jerrold Rosenbaum(Co-Founder & Chair Emeritus, Massachusetts General Hospital (MGH) Department of Psychiatry)inJacob Hooker(Co-Founder & Chief Executive Officer)inPranav Tadi(Executive Officer)Stephen Haggarty, PhD(Co-Founder & Professor of Neurology, Harvard Medical School)Dick Simon, MBA(Co-Founder)
BoardRyan Katz(Director)in
Co-investorsBonaventure Equity, LLCDolby Family VenturesIter InvestmentsMission BiocapitalPalo Santo VCRoute 66 Ventures+4 more
Ten63 develops drug-discovery technology that combines generative chemistry with quantum-accurate molecular simulation, including BEYOND (a large quantum chemistry model) and Sentinel (a virtual CSO for target selection), to design therapeutics against previously undruggable targets.
AI & Machine LearningBiotechDeep TechDurham, US
Mark A. Hallen(Founder & CTO)inMarcel Frenkel(Founder & CEO)inDamien Petty(Director)inJia Wei Xu(Director)Bruce Donald, PhD(Founder & Chair SAB)
Co-investorsCape Fear BioCapitalDFJ DragonFundDraper AssociatesDuke Capital PartnersSOSVAbbVie+4 more
Developing novel treatments based on the 12-LOX pathway for immuno-inflammatory diseases.
Co-investorsAlumni VenturesPappas CapitalSanofi VenturesAlexandriaGenesys CapitalJDRF T1D Fund+4 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
GoCheck
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.